Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Carisbamate (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors SK Life Science
  • Most Recent Events

    • 01 Aug 2012 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
    • 13 Jun 2012 Planned number of patients is 300 as reported by ClinicalTrials.gov.
    • 13 Jun 2012 Company added in association field as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top